Search
The EHA Guidelines Workshop, a meaningful and successful first Series!
November 2020 – April 2021
In the past six months, hematologists, clinicians, transfusion medicine specialists, oncologists, special nurses and researchers gathered virtually for the first EHA Guidelines Workshop series.
EHA Guidelines by Topic
AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Anemia
Recommendations regarding splenectomy in hereditary hemolytic anemias (2017)
Management of…
Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab
Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.
Read moreEHA-AHA Hematology Tutorial on Lymphoid Malignancies
Dates: October 18-20, 2019
Location: Yerevan, Armenia
Chairs: G Gaidano, S Danielyan, Y Hakobyan
2019 marks the 3rd time EHA is organizing a tutorial in collaboration with the Armenian Hematology Association (AHA), this time on “Lymphoid Malignancies”.
EHA leads Tutorial in Kazakhstan for better understanding of lymphomas
EHA, in collaboration with the Kazakhstan Cancer Society (KCS) and Kazakh Institute of Oncology and Radiology (KazIOR), organized its very first tutorial together on March 14-16 in Almaty, Kazakhstan.
Read moreGuidelines for hematologists
For guidance regarding COVID-19, see FAQ by the EHA SWG on Infections
EHA creates clinical practice guidelines for diagnosis and treatment of hematologic diseases.
EHA-PTHiT Hematology Mini Tutorial
Dates: April 12-13, 2021
Location: VIRTUAL
Chairs: I Hus (Poland), T Robak (Poland) & G Gaidano (Italy)
As a prelude to the full Tutorial planned for later this year, EHA and the Polish Society of Hematology and Transfusion (PTHiT) present a virtual 'mini…
Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial
Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- »